If you are a Healthcare Professional and you would like to log in to access this content, please click "Login".
You are now leaving the Lilly Medical Web site
Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Retsevmo ® ▼ (selpercatinib)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information:
Retsevmo Summary of Product Characteristics (SmPC)
What are the the dosing considerations for Retsevmo® ▼ (selpercatinib)?
Selpercatinib may be taken with or without food unless coadministered with a proton pump inhibitor.
recommended dose of selpercatinib in adult and adolescent patients
12 years of age or older is
mg orally twice daily for patients with an actual body weight ≥50
mg orally twice daily for patients with an actual body weight <50
should take the doses at approximately the same time every day.1
a patient vomits or misses a dose, the patient should be instructed
to take the next dose at its scheduled time. An additional dose
should not be taken.1
capsules must be swallowed whole if possible. lf a patient cannot
swallow the capsules, then alternative administration instructions
must be followed to ensure the integrity of the selpercatinib dose.2
may be taken with or without food unless coadministered with a PPI.1
is taken orally twice daily until disease progression or
unacceptable toxicity. Table 1
details the recommended dose of selpercatinib based on actual body
Retsevmo [summary of product characteristics]. Eli Lilly Nederland
B.V., The Netherlands.
Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Retevmo [package insert]. Indianapolis, IN: Eli Lilly and Company;
= proton pump inhibitor
medicinal product is subject to additional monitoring. This will
allow quick identification of new safety information. Healthcare
professionals are asked to report any suspected adverse reactions.
Date of Last Review:January 04, 2021
Are you satisfied with this content?
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at firstname.lastname@example.org